Literature DB >> 25784518

Effect of age on survival and causes of death after primary prevention implantable cardioverter-defibrillator implantation.

Laurent Fauchier1, Eloi Marijon2, Pascal Defaye3, Olivier Piot4, Nicolas Sadoul5, Marie-Cecile Perier6, Daniel Gras7, Didier Klug8, Vincent Algalarrondo9, Pierre Bordachar10, Jean-Claude Deharo11, Christophe Leclercq12, Dominique Babuty13, Serge Boveda14.   

Abstract

The benefit of implantable cardioverter-defibrillators (ICDs) remains controversial in elderly patients and may be attenuated by a greater risk of nonarrhythmic death. We examined the effect of age on outcomes after prophylactic ICD implantation. All patients with coronary artery disease or dilated cardiomyopathy implanted with an ICD for primary prevention of sudden cardiac death in 12 French medical centers were included in a retrospective observational study. The 5,534 ICD recipients were divided according to age: 18 to 59 years (n = 2,139), 60 to 74 years (n = 2,693), and ≥75 years (n = 702). Greater prevalences of coronary artery disease and atrial fibrillation at the time of implant were observed with increasing age (both p <0.0001). During a mean follow-up of 3.1 ± 2.0 years, the annual mortality rate increased with age: 3.1% per year for age 18 to 59 years, 5.7% per year for age 60 to 74 years, and 7.5% per year for age ≥75 years (p <0.001). Older age was independently associated with a greater risk of death (adjusted odds ratio 1.43, 95% confidence interval 1.14 to 1.80 for age 60 to 74 years; and adjusted odds ratio 1.65, 95% confidence interval 1.22 to 2.22 for age >75 years). Proportions of cardiac deaths (55.2%, 57.6%, and 57.0%, p = 0.84), including ICD-unresponsive sudden death (9.9%, 6.0%, and 10.6%, p = 0.08), and rates of appropriate ICD therapies were similar in the 3 age groups. Older age was independently associated with a higher rate of early complications and a lower rate of inappropriate therapies. In conclusion, older patients exhibited higher global mortality after ICD implantation for primary prevention, whereas rates of sudden deaths and of appropriate device therapies were similar across age groups.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25784518     DOI: 10.1016/j.amjcard.2015.02.031

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

1.  Subcutaneous implantable cardioverter-defibrillators: long-term results of the EFFORTLESS study.

Authors:  Pier D Lambiase; Dominic A Theuns; Francis Murgatroyd; Craig Barr; Lars Eckardt; Petr Neuzil; Marcoen Scholten; Margaret Hood; Jȕrgen Kuschyk; Amy J Brisben; Nathan Carter; Timothy M Stivland; Reinoud Knops; Lucas V A Boersma
Journal:  Eur Heart J       Date:  2022-06-01       Impact factor: 35.855

2.  The association between defibrillation shock energy and acute cardiac damage in patients with implantable cardioverter defibrillators.

Authors:  Daisuke Ishigaki; Daisuke Kutsuzawa; Takanori Arimoto; Tadateru Iwayama; Naoaki Hashimoto; Yu Kumagai; Satoshi Nishiyama; Hiroki Takahashi; Tetsuro Shishido; Takuya Miyamoto; Joji Nitobe; Akio Fukui; Tetsu Watanabe; Isao Kubota
Journal:  J Arrhythm       Date:  2016-04-26

3.  Subcutaneous Implantable Cardioverter Defibrillators Implantation Without Defibrillation Threshold Testing: A Single Center Experience.

Authors:  Bandar Al-Ghamdi; Azam Shafquat; Nadiah Alruwaili; Shisamma Emmanual; Mohamed Shoukri; Yaseen Mallawi
Journal:  Cardiol Res       Date:  2017-12-22

Review 4.  Predictors of mortality and ICD shock therapy in primary prophylactic ICD patients-A systematic review and meta-analysis.

Authors:  Leonard Bergau; Tobias Tichelbäcker; Barbora Kessel; Lars Lüthje; Thomas H Fischer; Tim Friede; Markus Zabel
Journal:  PLoS One       Date:  2017-10-17       Impact factor: 3.240

5.  The relevance of serum albumin among elderly patients with acute decompensated heart failure.

Authors:  Tuoyo O Mene-Afejuku; Ela-Anamaria Moisa; Adedoyin Akinlonu; Carissa Dumancas; Shushan Veranyan; Jose A Perez; Peggy Salazar; Shobhana Chaudhari; Gerald Pekler; Savi Mushiyev; Ferdinand Visco
Journal:  J Geriatr Cardiol       Date:  2019-07       Impact factor: 3.327

6.  Heart failure treatment in patients with cardiac implantable electronic devices: Opportunity for improvement.

Authors:  Samaneh Salimian; Marc W Deyell; Jason G Andrade; Santabhanu Chakrabarti; Matthew T Bennett; Andrew D Krahn; Nathaniel M Hawkins
Journal:  Heart Rhythm O2       Date:  2021-12-17

7.  Comparison of pharmacological treatment alone vs. treatment combined with implantable cardioverter defibrillator therapy in patients older than 75 years.

Authors:  Marcelino Cortés; Julia Anna Palfy; Marta Lopez; Juan Martínez; Ana Lucia Rivero; Ana Devesa; Juan Antonio Franco-Peláez; Sem Briongos; Mikel Taibo-Urquia; Juan Benezet; Jose-Manuel Rubio
Journal:  ESC Heart Fail       Date:  2018-06-24

8.  Primary Prevention Implantable Cardiac Defibrillators: A Townsville District Perspective.

Authors:  Nathan Engstrom; Geoffrey P Dobson; Kevin Ng; Hayley L Letson
Journal:  Front Cardiovasc Med       Date:  2020-10-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.